Galera Therapeutics, Inc.

Galera Therapeutics, Inc. is a biopharmaceutical company dedicated to transforming radiotherapy for cancer patients. Founded in 2012, the company focuses on developing novel therapies that can reduce the toxicities associated with radiation treatment while simultaneously enhancing its anti-cancer efficacy. Their unique scientific approach leverages superoxide dismutase mimetics, small molecules that mimic the body's natural defense against harmful superoxides produced during radiation therapy.

Galera's current pipeline includes two key products: avasopasem manganese, a radioprotective agent in late-stage development to mitigate severe oral mucositis, a common and debilitating side effect of head and neck cancer radiotherapy, and rucosopasem manganese, an anti-cancer agent in clinical development aimed at augmenting the effectiveness of radiation treatment for lung and pancreatic cancers. The company is committed to improving the quality of life and outcomes for cancer patients undergoing radiation therapy, with a focus on developing innovative therapies that address unmet medical needs.

Galera Therapeutics, Inc. is a biopharmaceutical company dedicated to transforming radiotherapy for cancer patients. They achieve this by developing innovative therapies designed to mitigate the toxic side effects of radiation therapy, improving the quality of life for patients while simultaneously enhancing the efficacy of the treatment itself. Their research focuses on the use of superoxide dismutase mimetics, which mimic the body's natural enzymes to protect healthy cells from radiation damage and boost the anti-cancer effects of radiation therapy.

Galera Therapeutics promotes a patient-centric culture focused on innovation and improving the lives of cancer patients. They are dedicated to developing novel therapies that transform radiotherapy, reducing toxicities and enhancing the efficacy of radiation treatment. The company's commitment to pioneering a new scientific approach is evident in their research and development efforts, and their team is driven by a shared desire to improve patient care.